Page last updated: 2024-11-06

temafloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Temafloxacin is a synthetic fluoroquinolone antibiotic that was developed in the late 1980s. It was originally marketed under the brand name Omniflox. Temafloxacin was found to have a broad spectrum of activity against gram-positive and gram-negative bacteria, including common pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli. It was also effective against some atypical bacteria, such as Mycoplasma pneumoniae and Chlamydia trachomatis. However, temafloxacin was associated with a significant risk of hepatotoxicity, a serious side effect that can cause liver damage. This led to its withdrawal from the market in most countries in the 1990s. Despite its withdrawal, temafloxacin continues to be studied for its potential use in treating certain infections, particularly in developing countries where alternative antibiotics may be limited. Research has focused on its mechanism of action, its pharmacokinetic properties, and its potential for drug interactions. While temafloxacin remains a valuable research tool, its use in clinical practice is currently limited due to safety concerns.'

temafloxacin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

temafloxacin : A racemate comprising equimolar amounts of (R)- and (S)-temafloxacin. Both enantiomers both exhibit similar pharmacological profiles. Temafloxacin was briefly used (either as the free base or as the hydrochloride salt) as an antibacterial drug but was withdrawn worldwide in 1992 following reports of serious side effects, including severe hypoglycaemia, haemolytic anaemia, liver and kidney dysfunction, anaphylaxis, and death. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID60021
CHEMBL ID277100
CHEBI ID77796
SCHEMBL ID48095
MeSH IDM0154422

Synonyms (55)

Synonym
ccris 6303
3-quinolinecarboxylic acid, 1,4-dihydro-1-(2,4-difluorophenyl)-6-fluoro-7- (3-methyl-1-piperazinyl)-4-oxo-
temafloxacinum [latin]
temafloxacine [french]
temafloxacina [spanish]
temafloxacin [inn:ban]
brn 4301726
1wz12gtt67 ,
unii-1wz12gtt67
a 62254
1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid
108319-06-8
t 1258
omniflox
abbott 62254
a63004
3-quinolinecarboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-
1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinoline-carboxylic acid
temafloxacin
(1)-temafloxacin
DB01405
1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
AKOS000280928
1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
CHEMBL277100
chebi:77796 ,
NCGC00183857-01
a-62254
tox21_113306
cas-108319-06-8
dtxsid7044132 ,
dtxcid5024132
temafloxacine
temafloxacina
temafloxacinum
FT-0631048
temafloxacin [mi]
temafloxacin [who-dd]
(+/-)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
temafloxacin [mart.]
3-quinolinecarboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-(+/-)-
temafloxacin [vandf]
temafloxacin [inn]
SCHEMBL48095
1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic
Q3983082
BCP12640
gtpl10866
a62254
6-fluoro-1-(2,4-difluorophenyl)-7-(3-methylpiperazin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
A908911
MS-27276
AKOS016844314
CS-0006360
HY-16487

Research Excerpts

Overview

Temafloxacin is an investigational fluoroquinolone with in vitro activity against common skin pathogens and a favorable pharmacokinetic profile. It appears to be a promising alternative to therapy with either ciprofloxacins or amoxicillin in the treatment of respiratory infections.

ExcerptReferenceRelevance
"Temafloxacin is a new broad-spectrum arylfluoroquinolone antimicrobial with an extended serum half-life."( Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women.
Philip, E; Stein, GE, 1992
)
2.03
"Temafloxacin is a new fluoroquinolone antibacterial agent. "( The effect of food on the bioavailability of temafloxacin. A review of 3 studies.
Granneman, GR; Mukherjee, D, 1992
)
1.99
"Temafloxacin appears to be a promising alternative to therapy with either ciprofloxacin or amoxicillin in the treatment of respiratory infections in high-risk patients, smokers, and the elderly."( Efficacy of temafloxacin versus ciprofloxacin or amoxicillin for lower respiratory tract infections in smokers and the elderly.
Davey, PG, 1991
)
1.38
"Temafloxacin is an investigational fluoroquinolone with in vitro activity against common skin pathogens and a favorable pharmacokinetic profile. "( Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin.
Jungkind, DL; Parish, LC, 1991
)
1.95
"Temafloxacin is a new fluoroquinolone that achieves a high urine concentration and has potent, broad-spectrum antimicrobial activity against most pathogens associated with urinary tract infections. "( Treatment of uncomplicated urinary tract infections with temafloxacin.
Iravani, A, 1991
)
1.97
"Temafloxacin is a new oral fluoroquinolone with broad-spectrum antimicrobial activity against gram-negative and gram-positive pathogens. "( Oral temafloxacin compared to norfloxacin for the treatment of complicated urinary tract infections.
Cox, CE, 1991
)
2.24
"Temafloxacin is an oral fluoroquinolone with potent in vitro activity against Neisseria gonorrhoeae. "( Single-dose oral temafloxacin versus parenteral ceftriaxone in the treatment of gonococcal urethritis/cervicitis.
Mogabgab, WJ, 1991
)
2.06
"Temafloxacin is a new antibacterial agent of the fluoroquinolone group. "( Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.
Kinzig, M; Mahr, G; Muth, P; Naber, KG; Sorgel, F, 1991
)
1.98
"Temafloxacin is a new fluoroquinolone with potent activity against several important bacteria. "( A review of the pharmacokinetic profile of temafloxacin.
Dudley, MN, 1991
)
1.99
"Temafloxacin is a new fluoroquinolone derivative currently under evaluation. "( [Experimental study on the hepatobiliary kinetics and excretion of temafloxacin. Evidence for production of active metabolites by the rabbit liver].
Blickle, JF; Brogard, JM; Dorner, M; Jehl, F; Koechlin, C; Monteil, H; Westphal, JF, 1991
)
1.96
"Temafloxacin (A-63004) is a new quinolone antibacterial agent with a broad spectrum of activity against gram-positive and gram-negative aerobes and anaerobes. "( Pharmacokinetics of temafloxacin in humans after single oral doses.
Carpentier, P; Granneman, GR; Morrison, PJ; Pernet, AG, 1991
)
2.05
"Temafloxacin is a new quinolone derivative presently under evaluation. "( Biliary elimination and hepatic disposition of a new fluoroquinolone, temafloxacin: experimental evaluation.
Blicklé, JF; Brogard, JM; Dorner, M; Jehl, F; Koechlin, C; Westphal, JF, 1990
)
1.96

Effects

Temafloxacin has been shown to be effective in the treatment of lower respiratory-tract infections, infections of the skin and associated structures, uncomplicated and complicated UTIs, bacterial prostatitis, and gonococcal and non-gonococcal urethritis and cervicitis. It has broad antimicrobial activity against gram-positive and gram-negative bacteria.

ExcerptReferenceRelevance
"Temafloxacin has been shown to be effective in the treatment of lower respiratory-tract infections, infections of the skin and associated structures, uncomplicated and complicated UTIs, bacterial prostatitis, and gonococcal and non-gonococcal urethritis and cervicitis."( Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Nix, DE; Symonds, WT, 1992
)
1.34
"Temafloxacin has broad antimicrobial activity against gram-positive and gram-negative bacteria, including improved in vitro activity against Streptococcus pneumoniae, Mycoplasma hominis, and anaerobic bacteria, including Bacteroides fragilis."( Temafloxacin: an overview.
Pankey, GA, 1991
)
2.45
"Temafloxacin has improved activity against pneumococci and its high oral bioavailability and excellent penetration into respiratory tissues now combine to provide a suitable profile for the management of a wider range of respiratory infections."( The role of temafloxacin in the community setting: an overview.
Ball, P, 1991
)
1.38

Toxicity

Temafloxacin has demonstrated an excellent safety profile, with reported overall rates of adverse events comparable to quinolone and nonquinolone reference agents. This article summarizes animal studies conducted to determine the toxic and mutagenic potential of temafl Oxacin.

ExcerptReferenceRelevance
" The frequency and severity of adverse events were similar in both groups, consisting primarily of digestive disorders and skin manifestations."( Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia.
Carbon, C; Chauvin, JP; Hazebroucq, J; Léophonte, P; Petitpretz, P, 1992
)
0.59
"During the Phase I, II, and III clinical development program, temafloxacin has demonstrated an excellent safety profile, with reported overall rates of adverse events comparable to quinolone and nonquinolone reference agents."( Temafloxacin: a safe antibiotic for the elderly, patients with comorbidities, and other special populations.
Pernet, AG, 1991
)
1.96
"This article summarizes animal studies conducted to determine the toxic and mutagenic potential of temafloxacin."( Comparison of organ-specific toxicity of temafloxacin in animals and humans.
Krasula, RW; Pernet, AG, 1991
)
0.76
" Adverse events were collated by spontaneous reporting by the patients or observations by investigators and, additionally in some studies, by the use of diary cards filled in by the patients."( Assessment of adverse events during drug development: experience with temafloxacin.
Norrby, SR; Pernet, AG, 1991
)
0.52
" The dams were monitored daily for adverse physical signs and maternal blood samples were collected for analyses of serum progesterone (P), 17 beta-estradiol (E2), and chorionic gonadotropin (CG)."( Developmental toxicity of temafloxacin hydrochloride in the long-tailed macaque (Macaca fascicularis).
Hendrickx, AG; Lasley, BL; Lehrer, SB; Tarantal, AF, 1990
)
0.58
" Generally, adverse effects reported in association with the fluoroquinolones have been those that could have been predicted by previous experience with non-fluorinated derivatives and by animal toxicity studies."( Safety and tolerability of fluoroquinolones.
Lietman, PS; Norrby, SR, 1993
)
0.29
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

The longer half-life of temafloxacin enables a once-daily dose regimen, whereas the usual recommended dosage of ciprofloxacins is twice daily. Pharmacokinetic analyses showed that cimetidine did not affect the rate or extent of temflamacin absorption.

ExcerptReferenceRelevance
" Pharmacokinetic analyses showed that cimetidine did not affect the rate or extent of temafloxacin absorption, as evidenced by unchanged peak plasma concentration, time to peak plasma concentration, and terminal-phase volume of distribution."( Effect of cimetidine on the pharmacokinetics of temafloxacin.
Granneman, GR; Locke, C; Sörgel, F; Stephan, U, 1992
)
0.76
"h) and terminal-phase half-life (9."( Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
Fuhr, U; Granneman, GR; Kinzig, M; Mahr, G; Muth, P; Nickel, P; Patterson, K; Sörgel, F; Stephan, U, 1992
)
0.67
"The purpose of the present work was to investigate the 48 h pharmacokinetic and biliary elimination of temafloxacin, administered intraduodenally at a single dose of 10 mg/kg to six conscious pigs provided with a double terminal choledocal fistula allowing the collection and the reinstillation of bile."( Pharmacokinetics and biliary elimination of temafloxacin in pigs.
Bresler, L; Didelot, JP; Hazebroucq, J; Jehl, F; Koechlin, C; Merle-Melet, M, 1992
)
0.76
" The longer half-life of temafloxacin enables a once-daily dose regimen, whereas the usual recommended dosage of ciprofloxacin is twice daily."( Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.
Kinzig, M; Mahr, G; Muth, P; Naber, KG; Sorgel, F, 1991
)
0.84
" Compared with the young group, mean peak plasma concentration in the elderly was 45% higher, the area under the plasma concentration versus time curve was 70% higher, the terminal elimination half-life was 18% higher, and the apparent beta-phase volume of distribution was 30% lower in the elderly group."( The influence of age on the pharmacokinetics of temafloxacin.
Granneman, GR; Guay, DR, 1991
)
0.54
" Theophylline pharmacokinetic parameters were determined noncompartmentally, and results of single and combined administration were compared."( Effect of temafloxacin on the pharmacokinetics of theophylline.
Callens, E; Chauvin, JP; Hazebroucq, J; Ruff, F; Santais, MC, 1991
)
0.68
"We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung."( Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991
)
0.5
" The long serum elimination half-life (approximately 8 h in patients with normal renal function) allows for single or twice-daily dosing."( A review of the pharmacokinetic profile of temafloxacin.
Dudley, MN, 1991
)
0.54
" The half-life (mean +/- standard deviation) increased from 10."( Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.
Braeckman, R; Craft, JC; Granneman, GR; Kraut, J; Shupien, S, 1991
)
1.72
"An in vitro pharmacodynamic system has been successfully adapted to simulate in vivo antimicrobial pharmacokinetics under anaerobic conditions."( Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
Krinke, AJ; Moody, JA; Rotschafer, JC; Vance-Bryan, K; Walker, KJ; Zabinski, RA, 1993
)
0.59
" Overall, results indicated (1) no marked differences in pharmacokinetic parameters in pregnant versus nonpregnant females, (2) fleroxacin levels in embryonic tissues were similar to maternal plasma levels, and (3) there was a correlation between exposure and embryolethal doses for all fluoroquinolones which resulted in embryolethality except norfloxacin."( Developmental toxicity of fleroxacin and comparative pharmacokinetics of four fluoroquinolones in the cynomolgus macaque (Macaca fascicularis).
Hendrickx, AG; Hummler, H; Richter, WF, 1993
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
"Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31

Bioavailability

Temafloxacin has improved activity against pneumococci. High oral bioavailability and excellent penetration into respiratory tissues now combine to provide a suitable profile for the management of a wider range of respiratory infections.

ExcerptReferenceRelevance
"The relative bioavailability of a single oral dose of temafloxacin given with and without enteral feeding was determined in 18 healthy male volunteers in a randomised crossover study."( The relative bioavailability of temafloxacin administered through a nasogastric tube with and without enteral feeding.
Lubowski, TJ; Nightingale, CH; Quintiliani, R; Sweeney, K, 1992
)
0.82
" The pharmacokinetics of 3 tablet formulations of temafloxacin were investigated in phase I studies in healthy adult volunteers, to determine whether the bioavailability is altered by the presence of food."( The effect of food on the bioavailability of temafloxacin. A review of 3 studies.
Granneman, GR; Mukherjee, D, 1992
)
0.8
" Comparable or greater antacid-associated reductions in relative bioavailability have been reported for other quinolones."( Effect of antacid medication on the pharmacokinetics of temafloxacin.
Birner, B; Granneman, GR; Mukherjee, D; Sörgel, F; Stephan, U, 1992
)
0.53
" Temafloxacin has improved activity against pneumococci and its high oral bioavailability and excellent penetration into respiratory tissues now combine to provide a suitable profile for the management of a wider range of respiratory infections."( The role of temafloxacin in the community setting: an overview.
Ball, P, 1991
)
1.57
" Studies in healthy volunteers indicate that the average bioavailability of temafloxacin exceeds 90%, with little intersubject variability."( A review of the pharmacokinetic profile of temafloxacin.
Dudley, MN, 1991
)
0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The chemistry, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, safety, drug interactions, and dosage and administration of lomefloxacin and temafloxACin, two new antimicrobials, are presented.

ExcerptRelevanceReference
" Analyses of variance found no significant differences among the dosage groups in total apparent clearances (CLT/F), renal clearances (CLR), or nonrenal clearances, which averaged 197, 119, and 78 ml/min, respectively."( Pharmacokinetics of temafloxacin in humans after multiple oral doses.
Carpentier, P; Granneman, GR; Morrison, PJ; Pernet, AG, 1992
)
0.61
" Because the altered temafloxacin pharmacokinetics appear to be primarily due to impaired renal function, this should be the main determinant of temafloxacin dosage in patients with liver disease."( Pharmacokinetics of temafloxacin in patients with liver impairment.
Fabian, W; Granneman, GR; Kinzig, M; Kirch, W; Locke, C; Mahr, G; Naber, KG; Nickel, P; Sörgel, F, 1992
)
0.93
" This may partly be explained by intertrial differences in dosage and study design."( Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
Fuhr, U; Granneman, GR; Kinzig, M; Mahr, G; Muth, P; Nickel, P; Patterson, K; Sörgel, F; Stephan, U, 1992
)
0.67
"The chemistry, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, safety, drug interactions, and dosage and administration of lomefloxacin and temafloxacin, two new antimicrobials, are presented."( Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Nix, DE; Symonds, WT, 1992
)
0.82
" The observation that serum (and tissue) concentrations of temafloxacin exceeded the minimal inhibitory concentration of the test organism over the whole dosing interval (12 hr), could account for its efficacy in severe pneumococcal disease."( Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy.
Azoulay-Dupuis, E; Bauchet, J; Pocidalo, JJ; Vallée, E, 1992
)
0.84
" A dose-response experiment was performed with clarithromycin at 50, 100, 200, or 300 mg/kg of body weight administered daily by gavage to mice infected with approximately 10(7) viable MAC."( Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.
Cynamon, MH; DeStefano, MS; Klemens, SP, 1992
)
0.28
" leprae; temafloxacin and sparfloxacin were the most active, being fully bactericidal at all three dosage schedules."( Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.
Gelber, RH; Iranmanesh, A; Murray, L; Siu, P; Tsang, M, 1992
)
0.7
" Based on an evaluation of adverse events among elderly patients with varying degrees of renal impairment, dosage adjustment of temafloxacin is necessary only for elderly patients with severe renal impairment."( Temafloxacin: a safe antibiotic for the elderly, patients with comorbidities, and other special populations.
Pernet, AG, 1991
)
1.93
" Evidence of cartilaginous joint damage was observed in puppies receiving oral temafloxacin, in young dogs receiving intravenous temafloxacin, and in a single dog receiving a lethal dosage in a dose range-finding study."( Comparison of organ-specific toxicity of temafloxacin in animals and humans.
Krasula, RW; Pernet, AG, 1991
)
0.77
" The longer half-life of temafloxacin enables a once-daily dose regimen, whereas the usual recommended dosage of ciprofloxacin is twice daily."( Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.
Kinzig, M; Mahr, G; Muth, P; Naber, KG; Sorgel, F, 1991
)
0.84
" As the difference in elimination half-life was small, alteration of the usual twice-daily dosage regimen is not necessary in the elderly."( The influence of age on the pharmacokinetics of temafloxacin.
Granneman, GR; Guay, DR, 1991
)
0.54
" Twelve healthy subjects (8 males, 4 females; average age and weight 34 years and 62 kg, respectively) were given oral controlled-release theophylline in an individualized dosage to achieve a target plasma level of 10 mg/L."( Effect of temafloxacin on the pharmacokinetics of theophylline.
Callens, E; Chauvin, JP; Hazebroucq, J; Ruff, F; Santais, MC, 1991
)
0.68
" Steady-state peak serum levels are approximately 1 mg/L per 100 mg oral dose administered; thus, the steady-state peak serum level after 600 mg bd oral dosing is approximately 6 mg/L."( A review of the pharmacokinetic profile of temafloxacin.
Dudley, MN, 1991
)
0.54
" Compared with the CLT/F in the subjects with normal renal function, CLT/F was reduced 60% in subjects with a CLCR of less than 40 ml/min, indicating that the dosage should be reduced by at least one-half for patients with comparable impairment."( Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.
Braeckman, R; Craft, JC; Granneman, GR; Kraut, J; Shupien, S, 1991
)
1.72
"0 hours after dosing with their OCS on days 5, 6, 7 and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH and LH by radioimmunoassay."( The lack of interaction between temafloxacin and combined oral contraceptive steroids.
Back, DJ; Mant, T; Martin, C; Millar, E; Morrison, P; Orme, M; Tjia, J, 1991
)
0.56
"0 hours after dosing with OCs on days 5, 6, 7, and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH, and LH by radioimmunoassay."( The lack of interaction between temafloxacin and combined oral contraceptive steroids.
Back, DJ; Mant, T; Martin, C; Millar, E; Morrison, P; Orme, M; Tjia, J, 1991
)
0.56
" Since intravenously dosed dogs eliminated 50% of the dose by nonrenal processes, urinary recoveries approaching two-thirds of the dose in humans were consistent with high, if not quantitative, absorption."( Pharmacokinetics of temafloxacin in humans after single oral doses.
Carpentier, P; Granneman, GR; Morrison, PJ; Pernet, AG, 1991
)
0.6
"The fluoroquinolones, temafloxacin, sarafloxacin, and difloxacin, are determined in the bulk drug substances and in a variety of dosage form using high-performance liquid chromatography (HPLC)."( Determination of temafloxacin, sarafloxacin, and difloxacin in bulk drug and dosage forms by high-performance liquid chromatography.
Bauer, JF; Elrod, L; Fornnarino, JR; Heathcote, DE; Krogh, SK; Linton, CL; Norris, BJ; Quick, JE, 1990
)
0.93
" Serum and blister fluid levels in excess of 1 mg/l were present for at least 8 h post dose, suggesting that a once or twice daily dosing regimen would be suitable for the treatment of infections caused by susceptible organisms."( The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.
Andrews, JM; Ashby, JP; Nye, K; Shi, YG; Wise, R, 1989
)
0.51
" In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (8)

ClassDescription
quinolone
amino acidA carboxylic acid containing one or more amino groups.
monocarboxylic acidAn oxoacid containing a single carboxy group.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
N-arylpiperazine
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency2.44130.000714.592883.7951AID1259369; AID1259392
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.52050.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (145)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID70138The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli SS1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID163440The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa K799/WT1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID69602Anti-bacterial activity was tested against Gram-negative EC-1 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID209928The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus pyogenes 2548 INDUC1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID30274The in vitro antibacterial activity as minimum inhibitory concentration against Acinetobacter sp. CMX 6691991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID70134The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli DC-21991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID68964Median dose against Escherichia coli Juhl cumulative mortalities in mouse after peroral administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID198020Antibacterial activity was determined against gram positive organism, Streptococcus faecalis (MGH-2)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID151052Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa UI-181991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID203265Median dose against Staphylococcus aureus NCTC 10649 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 2.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID70137The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli KNK4371991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID20940Compound was tested for its water solubility at pH 7.51991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID163437The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa A50071991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID203263Median dose against Staphylococcus aureus NCTC 10649 in mouse after peroral administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID17991Bioavailability2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID206047The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus epidermidis 35191991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1557330Haemolytic activity in human2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID200230Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (H228)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID197877Antibacterial activity was determined against gram positive organism, Staphylococcus aureus H2281991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID230838MIC ratio measured as the mean MICs of gram-negative bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID206857Anti-bacterial activity was tested against Gram-positive SA-13 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID164219Median dose against Pseudomonas aeruginosa A5007 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 2.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID57388Minimum inhibitory concentration against Escherichia coli DNA-gyrase in supercoiling assay1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID163438The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa BMH101991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID198174Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae (SV-1)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID123076The in vitro antibacterial activity as minimum inhibitory concentration against Micrococcus luteus ATCC 46981991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID20941Compound was tested for its water solubility in water.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID209122Anti-bacterial activity tested against Gram-positive SP1-1 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID19478Partition coefficient in octanol/water at pH 7.5 buffer.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID70135The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli H-5601991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID123077The in vitro antibacterial activity as minimum inhibitory concentration against Micrococcus luteus ATCC 93411991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID208921The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus bovis A51691991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID198316Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes (C203)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID163439The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa K799/611991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID144438Anti-bacterial activity tested against Mycobacterium smegmatis (ATCG 19420)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID203264Median dose against Staphylococcus aureus NCTC 10649 in mouse after peroral administration at a dose of 100xLD50 in TEST 2.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID200231Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (UC76)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID15883Calculated partition coefficient (clogP)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID324746Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID206495The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus A51771991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID68831Median dose against Escherichia coli Juhl in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID164216Median dose against Pseudomonas aeruginosa A5007 in mouse after peroral administration at a dose of 100xLD50 in TEST 2.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID151373Antibacterial activity was determined against gram negative organism, Providencia rettgeri. (M1771)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID208755The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus agalactiae CMX 5081991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID54107Minimum inhibitory concentration required to inhibit DNA gyrase supercoiling.1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID64254Antibacterial activity was determined against gram negative organism, E. coli(vogel)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID74723MIC ratio measured as the mean MICs of gram-negative bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID206493The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus 45 RAR21991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID63898Antibacterial activity was determined against gram negative organism, Enterobacter cloacae MA26461991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1557331Toxicity in human assessed as renal failure2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID164215Median dose against Pseudomonas aeruginosa A5007 in mouse after peroral administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID70136The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli Juhl1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID67545Activity against Enterobacter aerogenes2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID94063The in vitro antibacterial activity as minimum inhibitory concentration against Klebsiella pneumoniae ATCC 80451991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID69639Minimum inhibitory concentration against Escherichia coli2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods.
AID164218Median dose against Pseudomonas aeruginosa A5007 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID163892The in vitro antibacterial activity as minimum inhibitory concentration against Providencia stuartii CMX 6401991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID198021Antibacterial activity was determined against gram positive organism, Streptococcus faecalis MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID144009Anti-bacterial activity tested against Mycobacterium fortuitum (ATCG 6841)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID206496The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus ATCC 6538P1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID163782The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas cepacia 29611991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID209929The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus pyogenes 930 Const1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID209930The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus pyogenes EES611991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID68830Median dose against Escherichia coli Juhl in mouse after peroral administration at a dose of 100xLD50 in TEST 2.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID206492The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus 451991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID200234Antibacterial activity was determined against gram positive organism, Staphylococcus aureus UC761991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID64251Antibacterial activity was determined against gram negative organism, Escherichia coli vogel1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID150908Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa (UI-18)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID198176Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae SV-11991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID74734MIC ratio measured as the mean MICs of gram-positive bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID68832Median dose against Escherichia coli Juhl in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 2.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID203266Median dose against Staphylococcus aureus NCTC 10649 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID94123Antibacterial activity was determined against gram negative organism, K. pneumoniae (MGH-2)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID67866The in vitro antibacterial activity as minimum inhibitory concentration against Enterobacter aerogenes ATCC 130481991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID68578The in vitro antibacterial activity as minimum inhibitory concentration against Enterococcus faecium ATCC 80431991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID206497The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus CMX 5531991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID324747Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID324745Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID151374Antibacterial activity was determined against gram negative organism, Providencia rettgeri. M17711991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID164235Anti-bacterial activity tested against Gram-negative PA-7 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID198317Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes C2031991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1557329Toxicity in human assessed as thrombocytopenia2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID324753Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at 50 mg/kg/day after 9 months2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID230840MIC ratio measured as the mean MICs of gram-positive bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID209875Median dose against Streptococcus pneumoniae 6303 in mouse after peroral administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID94001Antibacterial activity was determined against gram negative organism, Klebsiella pneumoniae MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID63899Antibacterial activity against gram negative organism, Escherichia cloacae (MA2646)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID209876Median dose against Streptococcus pneumoniae 6303 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (204)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (5.39)18.7374
1990's174 (85.29)18.2507
2000's6 (2.94)29.6817
2010's7 (3.43)24.3611
2020's6 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.37 (24.57)
Research Supply Index5.49 (2.92)
Research Growth Index5.75 (4.65)
Search Engine Demand Index55.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (14.69%)5.53%
Reviews20 (9.48%)6.00%
Case Studies5 (2.37%)4.05%
Observational0 (0.00%)0.25%
Other155 (73.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]